Evidence map›Paper›PMID 39621243›Full record

ArticleMolecular diversity2025

Design and synthesis of glycyrrhetinic acid glycosides against acute lung injury and pulmonary fibrosis.

Wei Li, Jianrong Liu, Tianbo Wu, Xin Qiang, Yijie Peng, Quanyi Zhao, Dian He

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei Li *Institute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.
Jianrong Liu *Institute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.
Tianbo WuInstitute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.
Xin QiangInstitute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.
Yijie PengInstitute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.
Quanyi ZhaoInstitute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China. zhaoqy@lzu.edu.cn.
Dian HeInstitute of Medicinal Chemistry, School of Pharmacy of Lanzhou University, Lanzhou, 730000, China.

Funding

Drug Research project of Gansu Provincial Drug Administration 2022GSMPA0011Natural Science Foundation of Gansu Province of China 22JR5RA507
6 · The paper itself

Abstract

HMGB1 mediated signalling pathway plays an important role in acute injury and fibrosis in lung tissues. Glycyrrhizic acid (GL) is a HMGB1 inhibitor, and its aglycone (glycyrrhetinic acid, GA) is the major pharmacophore and plays the main role during binding to HMGB1. To improve selectivity for these lung diseases, a series of novel glycyrrhetinic acid glycosides targeting mannose acceptors in the respiratory tract and lung tissues were synthesised, and their biological activities were evaluated in vitro and in vivo. For normal lung cell lines WI-38 and Beas-2B, all the compounds but c6 showed reduced cytotoxicity vs the positive controls (GA and GL), IC

Indexed as

Acute Lung InjuryDrug DesignGlycosidesGlycyrrhetinic AcidPulmonary FibrosisA549 CellsAnimalsCell LineHMGB1 ProteinHumansMaleMiceRAW 264.7 CellsGlycosidesGlycyrrhetinic AcidHMGB1 ProteinAnti-inflammationAnti-pulmonary fibrosisGlycyrrhetinic acid glycoside

Identifiers

PMID39621243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.